open access

Vol 11, No 6 (2015)
Case report
Published online: 2016-03-08
Get Citation

Prolonged-release oxycodone/naloxone in the treatment of cancer pain — a case report

Aleksandra Modlińska
Oncol Clin Pract 2015;11(6):326-329.

open access

Vol 11, No 6 (2015)
CASE REPORT
Published online: 2016-03-08

Abstract

In moderate and strong cancer pain oxycodone has become one of the most effective and popular opioids. A combination of prolonged-release oxycodone with prolonged-release naloxone is a valued option among patients suffering from pain and opioid–induced bowel dysfunction (OIBD).
We present a case of a male cancer patient with chronic constipation effectively treated with oxycodone/naloxone
combination.

Abstract

In moderate and strong cancer pain oxycodone has become one of the most effective and popular opioids. A combination of prolonged-release oxycodone with prolonged-release naloxone is a valued option among patients suffering from pain and opioid–induced bowel dysfunction (OIBD).
We present a case of a male cancer patient with chronic constipation effectively treated with oxycodone/naloxone
combination.

Get Citation

Keywords

cancer pain, oxycodone, naloxone, opioid-induced bowel dysfunction

About this article
Title

Prolonged-release oxycodone/naloxone in the treatment of cancer pain — a case report

Journal

Oncology in Clinical Practice

Issue

Vol 11, No 6 (2015)

Article type

Case report

Pages

326-329

Published online

2016-03-08

Bibliographic record

Oncol Clin Pract 2015;11(6):326-329.

Keywords

cancer pain
oxycodone
naloxone
opioid-induced bowel dysfunction

Authors

Aleksandra Modlińska

References (22)
  1. Ciałkowska-Rysz A, Dzierżanowski T. Podstawowe zasady farmakoterapii bólu u chorych na nowotwory i inne przewlekłe, postępujące, zagrażające życiu choroby. Med Paliat. 2014; 6: 1–6.
  2. Breivik H, Collett B, Ventafridda V, et al. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain. 2006; 10(4): 287–333.
  3. Cleeland CS, Nakamura Y, Mendoza TR, et al. When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain. 1995; 61(2): 277–284.
  4. Caraceni A, Hanks G, Kaasa S, et al. European Palliative Care Research Collaborative (EPCRC), European Association for Palliative Care (EAPC). Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol. 2012; 13(2): e58–e68.
  5. van den Beuken-van Everdingen MHJ, de Rijke JM, Kessels AG, et al. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol. 2007; 18(9): 1437–1449.
  6. Gardiner C, Gott M, Ingleton C, et al. Attitudes of health care professionals to opioid prescribing in end-of-life care: a qualitative focus group study. J Pain Symptom Manage. 2012; 44(2): 206–214.
  7. Coluzzi F, Mattia C. Oxycodone. Pharmacological profile and clinical data in chronic pain management. Minerva Anestesiol. 2005; 71(7-8): 451–460.
  8. Wang YM, Liu ZW, Liu JL, et al. Efficacy and tolerability of oxycodone in moderate-severe cancer-related pain: A meta-analysis of randomized controlled trials. Exp Ther Med. 2012; 4(2): 249–254.
  9. Zacny JP, Gutierrez S. Characterizing the subjective, psychomotor, and physiological effects of oral oxycodone in non-drug-abusing volunteers. Psychopharmacology (Berl). 2003; 170(3): 242–254.
  10. Gimbel JS, Richards P, Portenoy RK. Controlled-release oxycodone for pain in diabetic neuropathy: a randomized controlled trial. Neurology. 2003; 60(6): 927–934.
  11. Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg. 2001; 182(5A Suppl): 11S–18S.
  12. Rosti G, Gatti A, Costantini A, et al. Opioid-related bowel dysfunction: prevalence and identification of predictive factors in a large sample of Italian patients on chronic treatment. Eur Rev Med Pharmacol Sci. 2010; 14(12): 1045–1050.
  13. Panchal SJ, Müller-Schwefe P, Wurzelmann JI. Opioid-induced bowel dysfunction: prevalence, pathophysiology and burden. Int J Clin Pract. 2007; 61(7): 1181–1187.
  14. Ueberall MA, Müller-Lissner S, Buschmann-Kramm C, et al. The Bowel Function Index for evaluating constipation in pain patients: definition of a reference range for a non-constipated population of pain patients. J Int Med Res. 2011; 39(1): 41–50.
  15. Melzack R, Wall PD. Pain mechanisms: a new theory. Science. 1965; 150(3699): 971–979.
  16. Hermanns K, Junker U, Nolte T. Prolonged-release oxycodone/naloxone in the treatment of neuropathic pain - results from a large observational study. Expert Opin Pharmacother. 2012; 13(3): 299–311.
  17. Schutter U, Grunert S, Meyer C, et al. Innovative pain therapy with a fixed combination of prolonged-release oxycodone/naloxone: a large observational study under conditions of daily practice. Curr Med Res Opin. 2010; 26(6): 1377–1387.
  18. Abramowitz L, Béziaud N, Caussé C, et al. Further validation of the psychometric properties of the Bowel Function Index for evaluating opioid-induced constipation (OIC). J Med Econ. 2013; 16(12): 1434–1441.
  19. Ahmedzai SH, Nauck F, Bar-Sela G, et al. A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain. Palliat Med. 2012; 26(1): 50–60.
  20. Ahmedzai SH, Leppert W, Janecki M, et al. Long-term safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate-to-severe chronic cancer pain. Support Care Cancer. 2015; 23(3): 823–830.
  21. Sandner-Kiesling A, Leyendecker P, Hopp M, et al. Long-term efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of non-cancer chronic pain. Int J Clin Pract. 2010; 64(6): 763–774.
  22. Löwenstein O, Leyendecker P, Lux EA, et al. Efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of moderate/severe chronic non-malignant pain: results of a prospectively designed pooled analysis of two randomised, double-blind clinical trials. BMC Clin Pharmacol. 2010; 10: 12.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl